Biologic Basis of Radiation Oncology

Clinical Radiation Oncology: Third Edition

Volumn , Issue , 2012, Pages 3-42

  Zeman, Elaine M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967016851     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1637-5.00001-8     Document Type: Chapter

References (341)

1. Heppner GH, Miller BE Tumor heterogeneity. Biological implications and therapeutic consequences. Cancer Metastasis Rev 1983, 2:5-23.
2. Heppner GH, Miller BE Therapeutic implications of tumor heterogeneity. Semin Oncol 1989, 16:91-105.
3. Suit H, Skates S, Taghian A, et al. Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother Oncol 1992, 25:251-260.
4. Höckel M, Schlenger K, Mitze M, et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996, 6:3-9.
5. Begg AC, Haustermans K, Hart AA The value of pretreatment cell kinetic parameters as predictors of radiotherapy outcome in head and neck cancer. A multicenter analysis. Radiother Oncol 1999, 50:13-23.
6. Norton L, Simon R Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977, 58:1735-1741.
7. Roentgen WC Uber eine neue Art von Strahlen. Sitzgsber Physik-Med Ges Wuerzburg 1895, 137:132-141.
8. Becquerel H Emission of the new radiations by metallic uranium. CR Acad Sci 1896, 122:1086-1088.
9. Curie P, Curie MS Sur une substance nouvelle radioactive, contenue dans la pechblende. CR Acad Sci 1898, 127:175-178.
10. Stenbeck T Ein Fall von Hautkrebs geheilt durch Rontgenbestrahlung. Mitteil Grenzgeb Med Chir 1900, 6:347-349.
11. Bernier J, Hall EJ, Giaccia A Radiation oncology. A century of achievements. Nature Rev Cancer 2004, 4:737-747.
12. Bergonié J, Tribondeau L Interpretation de quelques resultats de la radiotherapie. CR Acad Sci 1906, 143:983-988.
13. Regaud C Influence de la duree d'irradiation sur les effete determine's dans le testicule par le radium. CR Soc Biol 1922, 86:787-790.
14. Regaud C, Ferroux R Discordance des effets de rayons X, d'une part dans le testicule, par le peau, d'autre part dans la fractionnement de la dose. CR Soc Biol 1927, 97:431-434.
15. Regaud C, Ferroux R Uber den einflub des zeitfaktors auf die sterilisation des normalen und des neoplastischen zellnachwuchees durch radiotherapie. Strahlenther 1929, 31:495-508.
16. Coutard H Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. AJR Am J Roentgenol 1932, 28:313-331.
17. Coutard H Present conception of treatment of cancer of the larynx. Radiology 1940, 34:136-145.
18. Reisner A Untersuchungen uber die veranderungen der Hauttoleranz bei verschiedener Unterterlung. Strahlenther 1930, 37:779-787.
19. Quimby E, MacComb WS Further studies on the rate of recovery of human skin from the effects of roentgen or gamma rays. Radiology 1937, 29:305-312.
20. Paterson R The value of assessing and prescribing dosage in radiation therapy in simple terms. Radiology 1939, 32:221-227.
21. Ellis F Tolerance dose in radiotherapy with 200 keV X-rays. Br J Radiol 1942, 15:348-350.
22. Cohen L Radiation response and recovery: Radiobiological principles and their relation to clinical practice. The biological basis of radiation therapy 1966, 208-348. JB Lippincott, Philadelphia. E.E. Schwartz (Ed.).
23. Strandqvist M Studien uber die kumulative Wirkung der Roentgenstrahlen bei Fraktionierung. Acta Radiol Suppl 1944, 55:1-300.
24. Fletcher GH Keynote address. The scientific basis of the present and future practice of clinical radiotherapy. Int J Radiat Oncol Biol Phys 1983, 9:1073-1082.
25. Puck TT, Marcus PI Action of X-rays on mammalian cells. J Exp Med 1956, 103:653-666.
26. Puck TT, Marcus PI A rapid method for viable cell titration and clone production with HeLa cells in tissue culture. The use of X-irradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 1955, 41:432-437.
27. Hall EJ, Giaccia AJ Radiobiology for the radiologist 2006, Lippincott Williams & Wilkins, Philadelphia. ed 6.
28. Hutchinson F Molecular basis for action of ionizing radiations. Science 1961, 134:533-538.
29. Johansen I, Howard-Flanders P Macromolecular repair and free radical scavenging in the protection of bacteria against X-rays. Radiat Res 1965, 24:184-192.
30. Chapman JD, Dugle DL, Reuvers CJ, et al. Chemical radiosensitization studies with mammalian cells growing in vitro. Radiation research: biomedical, chemical and physical perspectives 1976, 752-760. Academic Press, New York. O. Nygaard, H. Adler, W.K. Sinclair (Eds.).
31. Ward JF Biochemistry of DNA lesions. Radiat Res 1985, 104:S103-S111.
32. Goodhead DT Physics of radiation action. Microscopic features that determine biological consequences. Radiation research 1895-1995, proceedings of the 10th international congress of radiation research. Vol 2: Congress lectures 1995, 43-48. Universitatsdruckerei H. Sturtz AG, Wurzburg. U. Hagen, D. Harder, H. Jung, C. Streffer (Eds.).
33. Cleaver JE Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968, 218:652-656.
34. Cleaver JE Xeroderma pigmentosum. A human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci USA 1969, 63:428-435.
35. Taylor AMR, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975, 258:427-429.
36. Wood RD, Mitchell M, Lindahl T Human DNA repair genes, 2005. Mutat Res 2005, 577:275-283.
37. Kastan MB, Bartek J Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
38. Painter RB, Young BR Radiosensitivity in ataxia-telangiectasia. A new explanation. Proc Natl Acad Sci USA 1980, 77:7315-7317.
39. Friedberg EC, Walker GC, Siede W, et al. DNA repair and mutagenesis 2006, ASM Press, Washington, DC.
40. Hanawalt PC, Spivak G Transcription-coupled DNA repair. Two decades of progress and surprises. Nature Rev Mol Cell Biol 2008, 9:958-970.
41. Powell S, McMillan TJ DNA damage and repair following treatment with ionizing radiation. Radiother Oncol 1990, 19:95-108.
42. Thompson LH, Brookman KW, Jones NJ, et al. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol 1990, 10:6160-6171.
43. Pardo B, Gomez-Gonzalez B, Aguilera A DNA double-strand break repair. How to fix a broken relationship. Cell Molec Life Sci 2009, 66:1039-1056.
44. Narod SA, Foulkes WD BRCA1 and BRCA2. 1994 and beyond. Nature Rev Cancer 2004, 4:665-676.
45. Modrich P Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006, 281:30305-30309.
46. Lipkin SM, Wang V, Jacoby R, et al. MLH3. A novel DNA mismatch repair gene associated with mammalian microsatellite instability. Nature Genet 2000, 24:27-35.
47. Peltomaki P, Vassen HF Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997, 113:1146-1158.
48. Lynch PM, Lanspa SJ, Snyder CL, et al. Review of the Lynch syndrome. History, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009, 76:1-18.
49. Steel GG, Adams GE, Peckham MJ The biological basis of radiotherapy 1983, Elsevier, New York.
50. Savage JR, Simpson PJ FISH "painting" patterns resulting from complex exchanges. Mutat Res 1994, 312:51-60.
51. Anderson RM, Marsden SJ, Wright EG, et al. Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha particles. Int J Radiat Biol 2000, 76:31-42.
52. Elkind MM, Whitmore GF The radiobiology of cultured mammalian cells 1967, Gordon and Breach Science Publishers, New York.
53. Kerr JFR, Wyllie AH, Currie AR Apoptosis. A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
54. Meyn R Apoptosis and response to radiation. Implications for radiation therapy. Oncology 1997, 11:349-356.
55. Lea DE Actions of radiation on living cells 1946, Cambridge University Press, Cambridge.
56. Zimmer KG That was the radiobiology that was. A selected bibliography and some comments. Advances in radiation biology 1981, vol 9:411-467. Academic Press, New York.
57. Alper T Keynote address. Survival curve models. Radiation biology in cancer research 1980, 3-18. Raven Press, New York. R.E. Meyn, H.R. Withers (Eds.).
58. Kellerer AM, Rossi HH The theory of dual radiation action. Curr Top Radiat Res Q 1972, 8:85-158.
59. Chadwick KH, Leenhouts HP A molecular theory of cell survival. Phys Med Biol 1973, 18:78-87.
60. Puck TT, Marcus PI, Cieciura SJ Clonal growth of mammalian cells in vitro: growth characteristics of colonies from single HeLa cells with and without a "feeder" layer. J Exp Med 1956, 103:273-284.
61. Puck TT, Morkovin D, Marcus PI, et al. Action of X-rays on mammalian cells. II. Survival curves of cells from normal tissues. J Exp Med 1957, 106:485-500.
62. Alper T, Gillies NE, Elkind MM The sigmoid survival curve in radiobiology. Nature 1960, 186:1062-1063.
63. Alper T, Fowler JF, Morgan RL, et al. The characterization of the "type C" survival curve. Br J Radiol 1962, 35:722-723.
64. Hewitt HB, Wilson CW A survival curve for cells irradiated in vivo. Nature 1959, 183:1060-1061.
65. Till JE, McCulloch EA A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-221.
66. McCulloch EA, Till JE The sensitivity of cells from normal mouse bone marrow to gamma radiation in vitro and in vivo. Radiat Res 1962, 16:822-832.
67. Withers HR The dose-survival relationship for irradiation of epithelial cells of mouse skin. Br J Radiol 1967, 40:187-194.
68. Withers HR, Elkind MM Radiosensitivity and fractionation response of crypt cells of mouse jejunum. Radiat Res 1969, 38:598-613.
69. Withers HR, Elkind MM Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiations. Int J Radiat Biol 1970, 17:261-267.
70. Hill RP, Bush RS A lung-colony assay to determine the radiosensitivity of cells of a solid tumor. Int J Radiat Biol 1969, 15:435-444.
71. Rockwell S, Kallman RF Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res 1973, 53:281-294.
72. Fowler JF, Morgan RL, Silvester JA, et al. Experiments with fractionated X-ray treatment of the skin of pigs. I. Fractionation up to 28 days. Br J Radiol 1963, 36:188-196.
73. Thomlinson RH An experimental method for comparing treatments of intact malignant tumours in animals and its application to the use of oxygen in radiotherapy. Br J Cancer 1960, 14:555-576.
74. Suit HD, Shalek RJ Response of spontaneous mammary carcinoma of the C3H mouse to x-irradiation given under conditions of local tissue anoxia. J Natl Cancer Inst 1963, 31:497-509.
75. Elkind MM, Sutton H X-ray damage and recovery in mammalian cells. Nature 1959, 184:1293-1295.
76. Elkind MM, Sutton H Radiation response of mammalian cells grown in culture. I. Repair of X-ray damage in surviving Chinese hamster cells. Radiat Res 1960, 13:556-593.
77. Belli JA, Dicus GJ, Bonte FJ Radiation response of mammalian tumor cells. I. Repair of sublethal damage in vivo. J Natl Cancer Inst 1967, 38:673-682.
78. Emery EW, Denekamp J, Ball MM Survival of mouse skin epithelial cells following single and divided doses of X-rays. Radiat Res 1970, 41:450-466.
79. Phillips RA, Tolmach LJ Repair of potentially lethal damage in X-irradiated HeLa cells. Radiat Res 1966, 29:413-432.
80. Hahn GM, Little JB Plateau phase cultures of mammalian cells: an in vitro model for human cancer. Curr Top Radiat Res Q 1972, 8:39-83.
81. Little JB, Hahn GM, Frindel E, et al. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 1973, 106:689-694.
82. Belli JA, Shelton M Potentially lethal radiation damage. Repair by mammalian cells in culture. Science 1969, 165:490-492.
83. Nagasawa H, Little JB Induction of chromosome aberrations and sister chromatid exchanges by X-rays in density inhibited cultures of mouse 10T1/2 cells. Radiat Res 1981, 87:538-551.
84. Cornforth MN, Bedford JS X-ray-induced breakage and rejoining of human interphase chromosomes. Science 1983, 222:1141-1143.
85. Howard A, Pelc SR Nuclear incorporation of P32 as demonstrated by autoradiographs. Exp Cell Res 1951, 2:178-198.
86. Terasima T, Tolmach LJ Changes in X-ray sensitivity of HeLa cells during the division cycle. Nature 1961, 190:1210-1211.
87. Terasima T, Tolmach LJ Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 1963, 3:11-33.
88. Eidinoff ML, Rich MA Growth inhibition of a human tumor cell strain by 5-fluoro-2'-deoxyuridine:. Time parameters for subsequent reversal by thymidine. Cancer Res 1959, 19:521-529.
89. Sinclair WK The combined effect of hydroxyurea and X-rays on Chinese hamster cells in vitro. Cancer Res 1968, 28:190-206.
90. Withers HR, Mason K, Reid BO, et al. Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer 1974, 34:39-47.
91. Crissman HA, Mullaney PF, Steinkamp JA Methods and applications of flow systems for analysis and sorting of mammalian cells. Methods in cell biology 1975, vol 9:179-246. Academic Press, New York.
92. Sinclair WK, Morton RA X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966, 29:450-474.
93. Sinclair WK Cyclic X-ray responses in mammalian cells in vitro. Radiat Res 1968, 33:620-643.
94. Dewey WC, Stone LE, Miller HJ, et al. Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells X-irradiated during different phases of the cell cycle. Radiat Res 1971, 47:672-688.
95. Canti RG, Spear FG The effect of gamma irradiation on cell division in tissue culture in vitro. Proc R Soc Med Biol 1927, 102:92-101.
96. Little JB Differential response of rapidly and slowly proliferating human cells to X-irradiation. Radiology 1969, 97:303-313.
97. Walters RA, Gurley LR, Tobey RA Effects of caffeine on radiation-induced phenomena associated with cell cycle traverse of mammalian cells. Biophys J 1974, 14:99-118.
98. Withers HR Cell cycle redistribution as a factor in multifraction irradiation. Radiology 1975, 114:199-202.
99. Bedford JS, Mitchell JB Dose-rate effects in synchronous mammalian cells in culture. Radiat Res 1973, 54:316-327.
100. Bedford JS, Mitchell JB, Fox MH Variations in responses of several mammalian cell lines to low dose-rate irradiation. Radiation biology in cancer research 1980, 251-262. Raven Press, New York. R.E. Meyn, H.R. Withers (Eds.).
101. Blakely EA, Chang PY, Lommel L Cell-cycle-dependent recovery from heavy-ion damage in G1 phase cells. Radiat Res Suppl 1985, 104:5145.
102. Withers HR, Thames HD, Peters LJ Biological bases for high RBE values for late effects of neutron irradiation. Int J Radiat Oncol Biol Phys 1982, 8:2071.
103. Barendsen GW Responses of cultured cells, tumors and normal tissues to radiations of different linear energy transfer. Curr Top Radiat Res Q 1968, 4:293-356.
104. Kaplan HS Historic milestones in radiobiology and radiation therapy. Semin Oncol 1979, 6:479-489.
105. Thomlinson RH, Gray LH The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
106. Powers WE, Tolmach LJ A multicomponent X-ray survival curve for mouse lymphosarcoma cells irradiated. Nature 1963, 197:710-711.
107. Moulder JE, Rockwell S Hypoxic fractions of solid tumors. Experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 1984, 10:695-712.
108. Palcic B, Ld S Reduced oxygen enhancement ratio at low doses of ionizing radiation. Radiat Res 1984, 100:328-339.
109. Brown JM, Yu NY Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: a preliminary report. Int J Radiat Oncol Biol Phys 1984, 10:1207-1212.
110. Howard-Flanders P, Moore D The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen. I. A search for an effect of oxygen 0.02 second after pulsed irradiation. Radiat Res 1958, 9:422-437.
111. Michael BD, Adams GE, Hewitt HB, et al. A posteffect of oxygen in irradiated bacteria: a submillisecond fast mixing study. Radiat Res 1973, 54:239-251.
112. Alper T, Howard-Flanders P The role of oxygen in modifying the radiosensitivity of E. coli B. Nature 1956, 178:978-979.
113. Fowler JF, Morgan RL, Wood CAP Pretherapeutic experiments with the fast neutron beam from the Medical Research Council Cyclotron. I. The biological and physical advantages and problems of neutron therapy. Br J Radiol 1963, 36:163-173.
114. van Putten LM, Kallman RF Oxygenation status of a transplantable tumor during fractionated radiotherapy. J Natl Cancer Inst 1968, 40:441-451.
115. Kallman RF The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972, 105:135-142.
116. Brown JM Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979, 52:650-656.
117. Dewhirst MW Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009, 172:653-665.
118. Chaplin DJ, Durand RE, Olive PL Acute hypoxia in tumors: implication for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986, 12:1279-1282.
119. Dische S Radiotherapy and anemia: The clinical experience. Radiother Oncol Suppl 1991, 20:35-40.
120. Dische S What have we learnt from hyperbaric oxygen?. Radiother Oncol Suppl 1991, 20:71-74.
121. Basic clinical radiobiology 2009, Hodder Arnold, London. ed 4. M. Joiner, A. van der Kogel (Eds.).
122. Dische S Chemical sensitizers for hypoxic cells. A decade of experience in clinical radiotherapy. Radiother Oncol 1985, 3:97-115.
123. Overgaard J, Hansen HS, Anderson AP, et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx. Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989, 16:1065-1068.
124. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14:831-838.
125. Höckel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50.
126. Schneiderman G, Goldstick TK Oxygen electrode design criteria and performance characteristics: recessed cathode. J Appl Physiol 1978, 45:145-154.
127. Varghese AJ, Whitmore GF Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 1980, 40:2165-2169.
128. Chapman JD, Franko AJ, Sharplin J A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981, 43:546-550.
129. Urtasun RC, Koch CJ, Franko AF, et al. A novel technique for measuring human tissue pO2 at the cellular level. Br J Cancer 1986, 54:453-457.
130. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using F-18 fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995, 32:391-398.
131. 19F magnetic resonance spectroscopy. Int J Radiat Biol 1990, 58:1025-1034.
132. Cline JM, Thrall DE, Rosner GL, et al. Distribution of the hypoxia marker CCI-103F in canine tumors. Int J Radiat Oncol Biol Phys 1994, 28:921-933.
133. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix. First report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997, 37.
134. Raleigh JA, Dewhirst MW, Thrall DE Measuring tumor hypoxia. Semin Radiat Oncol 1996, 6:37-45.
135. Zeman EM, Calkins DP, Cline JM, et al. The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 1993, 27:891-898.
136. Bussink J, Kaanders JH, Rijken PF, et al. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 2000, 153:398-404.
137. Nordsmark M, Loncaster J, Chou S-C, et al. Invasive oxygen measurements and pimonidazole labelling in human cervix carcinomas. Int J Radiat Oncol Biol Phys 2001, 49:581-586.
138. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole. A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998, 71:270-277.
139. Arteel GE, Thurman RG, Yates JM, et al. Evidence that hypoxia markers detect oxygen gradients in liver. Pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995, 73:889-895.
140. Arteel GE, Thurman RG, Raleigh JA Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998, 253:743-750.
141. Yin M, Zhong Z, Connor HD, et al. Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo. Am J Renal Physiol 2002, 282:417-423.
142. Vordermark D, Brown JM Endogenous markers of tumor hypoxia. Predictors of clinical radiation resistance?. Strahlenther Onkol 2003, 179:801-811.
143. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008, 4:342-351.
144. Vordermark D, Katzer A, Baier D, et al. Cell type-specific association of hypoxia-inducible factor-1 alpha (HIF-1α) protein accumulation and radiobiologic tumor hypoxia. Int J Radiat Oncol Biol Phys 2004, 58:1242-1250.
145. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001, 61:8924-8929.
146. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001, 7:928-934.
147. Airley R, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix. Relationship to pimonidazole binding. Int J Cancer 2003, 104:85-91.
148. Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1). A potential marker of prognosis in rectal carcinoma?. Br J Cancer 2003, 89:870-876.
149. Hoogsteen IJ, Marres HA, Bussink J, et al. Tumor microenvironment in head and neck squamous cell carcinomas. Predictive value and clinical relevance of hypoxic markers: a review. Head Neck 2007, 29:591-604.
150. Bache M, Kappler M, Said HIM, et al. Detection and specific targeting of hypoxic regions within solid tumors. Current preclinical and clinical strategies. Curr Med Chem 2008, 15:322-338.
151. Hall EJ High-LET radiations. Cancer: a comprehensive treatise 1977, vol 6:281-315. Plenum Press, New York.
152. Rockwell S, Baserga SJ, Ps K Artificial blood substitutes in radiotherapy. Radiation research 1895-1995: proceedings of the tenth international congress of radiation research 1996, vol 2:795-798. Universitätsdruckerei H. Stürtz AG, Wurzburg.
153. Gerweck LE, Gillette EL, Dewey WC Killing of Chinese hamster cells in vitro by heating under hypoxic or aerobic conditions. Eur J Cancer 1974, 10:691-693.
154. Yuhas JM, Spellman JM, Culo F The role of WR 2721 in radiotherapy and/or chemotherapy. Radiation sensitizers 1980, 303-308. Masson, New York. L. Brady (Ed.).
155. Horsman MR, Chaplin DJ, Overgaard J The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother Oncol Suppl 1991, 20:47-52.
156. Lee I, Kim JH, Levitt SH, et al. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys 1992, 22:425-429.
157. Zeman EM, Brown JM, Lemmon MJ, et al. SR 4233. A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986, 12:1239-1242.
158. Brown JM SR 4233 (tirapazamine). A new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 1993, 67:1163-1170.
159. Adams GE, Dewey DL Hydrated electrons and radiobiological sensitization. Biochem Biophys Res Commun 1963, 12:473-477.
160. Brown JM, Workman P Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 1980, 82:171-190.
161. Brown JM Clinical trials of radiosensitizers. What should we expect?. Int J Radiat Oncol Biol Phys 1984, 10:425-429.
162. Brown JM, Yu NY, Brown DM, et al. SR 2508. A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 1981, 7:695-703.
163. Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995, 32:567-576.
164. Szybalski W Properties and applications of halogenated deoxyribonucleic acids. The molecular basis of neoplasia (a collection of papers presented at the fifteenth annual symposium on fundamental cancer research, 1961) 1962, 147-171. University of Texas Press, Austin.
165. Cecchini S, Girouard S, Huels MA, et al. Single-strand-specific radiosensitization of DNA by bromodeoxyuridine. Radiat Res 2004, 162:604-615.
166. Bagshaw MA, Doggett RL, Smith KC Intra-arterial 5-bromodeoxyuridine and x-ray therapy. AJR Am J Roentgenol 1967, 99:889-894.
167. Kinsella T, Mitchell J, Russo A, et al. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects. Int J Radiat Oncol Biol Phys 1984, 10:139-146.
168. Mitchell J, Kinsella T, Russo A, et al. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR). Int J Radiat Oncol Biol Phys 1983, 9:457-463.
169. Mitchell JB, Russo A, Cook JA, et al. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol 1989, 56:827-836.
170. Rodriguez R, Ritter MA, Fowler JF, et al. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994, 29:105-113.
171. Lawrence TS, Davis MA, Mayburn J, et al. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990, 18:1393-1398.
172. Brown JM, Lemmon MJ Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990, 50:7745-7749.
173. Brown JM, Siim BG Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 1996, 6:22-36.
174. Adams GE The Henry S. Kaplan Award Lecture: The search for specificity. Radiation research 1895-1995 1995, vol 2:33-40. Universitatsdruckerei H. Sturtz AG, Wurzburg, Congress Lectures.
175. Brown JM Cytotoxic effects of the hypoxic cell radiosensitizer Ro 07-0582 to tumor cells in vivo. Radiat Res 1977, 72:469-486.
176. Denekamp J, McNally NJ The magnitude of hypoxic cell cytotoxicity of misonidazole in human tumours. Br J Radiol 1978, 51:747-748.
177. Adams GE, Ahmed I, Sheldon PW, et al. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 1984, 49:571-578.
178. Haffty BG, Son YH, Sasaki CT, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993, 27:241-250.
179. Marcu L, Olver I Tirapazamine. From bench to clinical trials. Curr Clin Pharmacol 2006, 1:71-879.
180. Koch CJ Unusual oxygen concentration dependence of toxicity of SR 4233, a hypoxic cell toxin. Cancer Res 1993, 53:3992-3997.
181. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer. A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005, 79-87.
182. Patt HM Cysteine protection against x-irradiation. Science 1949, 110:213-214.
183. Schuchter LM, Glick J The current status of WR-2721 (amifostine). A chemotherapy and radiation therapy protector. Biol Ther Cancer 1993, 3:1-10.
184. 35S-WR 2721 biodistribution. Radiat Res 1984, 97:598-607.
185. Rojas A, Stewart FA, Soranson JA, et al. Fractionation studies with WR 2721. Normal tissues and tumor. Radiother Oncol 1987, 6:51-60.
186. Yuhas JM, Storer JB Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969, 42:331-335.
187. Yuhas JM Improvement of lung tumor radiotherapy through differential chemoprotection of normal and tumor tissue. J Natl Cancer Inst 1972, 48:1255-1257.
188. Glover D, Glick JH, Weiler C, et al. Phase I/II trials of WR 2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1986, 12:1509-1512.
189. Glover DJ, Glick JH, Weiler C, et al. WR 2721 protects against the hematologic toxicity of cyclophosphamide. A controlled phase II trial. J Clin Oncol 1986, 4:584-588.
190. Kligerman MM, Turrisi AT, Urtasun RC, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14:1119-1122.
191. Delaney JP, Bonsack ME, Felemovicius I Misoprostol in the intestinal lumen protects against radiation injury of the mucosa of the small bowel. Radiat Res 1994, 137:405-409.
192. Hanson WR, Marks JE, Reddy SP, et al. Protection from radiation-induced oral mucositis by misoprostol, a Prostaglandin E(1) analog. A placebo-controlled, double-blind clinical trial. Am J Therapeutics 1995, 2:850-857.
193. Moulder JE Pharmacological intervention to prevent or ameliorate chronic radiation injuries. Semin Radiat Oncol 2003, 13:73-84.
194. Delanian S, Lefaix JL The radiation-induced fibroatrophic process. Therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004, 73:119-131.
195. Komarov PG, Komarova EA, Kondratove RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
196. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008, 320:226-230.
197. Rubin P, Casarett GW Clinical radiation pathology 1968, WB Saunders, Philadelphia.
198. Michalowski A Effects of radiation on normal tissues. Hypothetical mechanisms and limitations of in situ assays of clonogenicity. Radiat Environ Biophys 1981, 19:157-172.
199. Mendelsohn ML The growth fraction. A new concept applied to tumors. Science 1960, 132:1496-1497.
200. Mendelsohn ML, Dohan FC, Moore HA Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. J Natl Cancer Inst 1960, 25:477-484.
201. Lajtha LG On the concepts of the cell cycle. Cell Compar Physiol 1963, 62:143-145.
202. Dethlefsen LA In quest of the quaint quiescent cells. Radiation biology in cancer research 1980, 415-435. Raven Press, New York. R.E. Meyn, H.R. Withers (Eds.).
203. Steel GG Growth kinetics of tumours 1977, Clarendon Press, Oxford.
204. Steel GG The heyday of cell population kinetics. Insights from the 1960s and 1970s. Semin Radiat Oncol 1993, 3:78-83.
205. Quastler H, Sherman FG Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 1959, 17:420-438.
206. Tannock IF, Hill RP, Bristow RG, et al. The basic science of oncology 2005, McGraw-Hill, New York. ed 4.
207. Tannock IF The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Br J Cancer 1968, 22:258-273.
208. Steel GG Cell loss from experimental tumors. Cell Tissue Kinet 1968, 1:193-207.
209. McBride WH, Withers HR Biological basis of radiation therapy. Principles and practice of radiation oncology 2008, 76-108. Lippincott Williams & Wilkins, Philadelphia. ed 5. E.C. Halperin, C.A. Perez, L.W. Brady (Eds.).
210. Begg AC, McNally NJ, Shrieve DC, et al. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985, 6:620-626.
211. Wilson GD, McNally NJ, Dische S Measurement of cell kinetics in human tumors in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1988, 58:423-431.
212. Bentzen SM Estimation of radiobiological parameters from clinical data. Radiation research 1895-1995: vol 2, Congress lectures 1995, 833-838. Universitatsdruckerei H. Sturtz AG, Wurzburg. U. Hagen, H. Jung, C. Streffer (Eds.).
213. Begg AC, Hofland I, Van Glabekke M Predictive value of potential doubling time for radiotherapy of head and neck tumour patients. Results from the EORTC Cooperative Trial 22857. Semin Radiat Oncol 1992, 2:22-25.
214. Withers HR, Taylor JMG, Maciejewski B The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
215. Thames HD, Ruifrok ACC, Milas L, et al. Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma. Downregulation of apoptosis as a possible mechanism. Int J Radiat Oncol Biol Phys 1996, 35:951-962.
216. Fowler JF The James Kirk Memorial Lecture. What next in fractionated radiotherapy?. Br J Cancer Suppl 1984, 46:285-300.
217. Fowler JF Non-standard fractionation in radiotherapy. Int J Radiat Oncol Biol Phys 1984, 10:755-759.
218. Fowler JF The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.
219. Fowler JF Review. Total doses in fractionated radiotherapy: implications of the new radiobiological data. Int J Radiat Oncol Biol Phys 1984, 46:103-120.
220. Hermens AF, Barendsen GW Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after X-irradiation. Eur J Cancer 1969, 5:173-189.
221. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
222. Dorr W, Hendry JH Consequential late effects in normal tissues. Radiother Oncol 2001, 61:223-231.
223. Hemplemann LH, Lisco H, Hoffman JG The acute radiation syndrome. A study of nine cases and a review of the problem. Ann Intern Med 1952, 36:279-510.
224. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. Report to the General Assembly with Annexes. Vienna, United Nations Publications, 1994.
225. Mettler FA, Upton AC Medical effects of ionizing radiation 2008, WB Saunders, Philadelphia. ed 3.
226. Shipman TL, Lushbaugh CC, Peterson D, et al. Acute radiation death resulting from an accidental nuclear critical excursion. J Occup Med Suppl 1961, 3:146-192.
227. Karas JS, Stanbury JB Fatal radiation syndrome from an accidental nuclear excursion. N Engl J Med 1965, 272:755-761.
228. Cogan CJ, Donaldson DD, Reese AB Clinical and pathological characteristics of the radiation cataract. Arch Ophthalmol 1952, 47:55.
229. Committee on Biological Effects of Ionizing Radiation Health effects of exposure to low levels of ionizing radiation 1990, National Academy Press, Washington, DC.
230. Upton AC The dose-response relation in radiation-induced cancer. Cancer Res 1961, 21:717-729.
231. International Commission on Radiological Protection 1990 Recommendations, publication no. 60. annals of the icrp, vol 21 1991, Pergamon Press, Oxford.
232. Stewart A, Webb D, Hewitt B A survey of childhood malignancies. Br Med J 1958, 1:1495.
233. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci USA 2003, 100:13761-13766.
234. Brenner DJ, Hall EJ Computed tomography: An increasing source of radiation exposure. N Engl J Med 2007, 357:2277-2284.
235. Brenner D, Elliston C, Hall E, et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001, 176:289-296.
236. Brenner DJ Estimating cancer risks from pediatric CT. Going from the qualitative to the quantitative. Pediatr Radiol 2002, 32:228-233.
237. Tubiana M, Aurengo A, Averbeck D, et al. The debate on the use of linear no threshold for assessing the effects of low doses. J Radiol Prot 2006, 26:317-324.
238. Larson DB, Rader SB, Forman HP, et al. Informing parents about CT radiation exposure in children. It's OK to tell them. AJR Am J Roentgenol 2007, 189:271-275.
239. Fajardo LF Pathology of radiation injury 1982, Masson, New York.
240. Hallahan DE Radiation-mediated gene expression in the pathogenesis of the clinical radiation response. Semin Radiat Oncol 1996, 6:250-267.
241. Hallahan DE, Haimovitz-Friedman A, Kufe DW, et al. The role of cytokines in radiation oncology. Important Adv Oncol 1993, 71-80.
242. Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, et al. Using biological markers to predict risk of radiation injury. Semin Radiat Oncol 2007, 17:89-98.
243. Madani I, De Ruyck K, Goeminne H, et al. Predicting risk of radiation-induced lung injury. J Thorac Oncol 2007, 2:864-874.
244. Haimovitz-Friedman A, Kolesnick RN, Fuks Z Modulation of the apoptotic response: potential for improving the outcome in clinical radiotherapy. Semin Radiat Oncol 1996, 6:273-283.
245. Withers HR, Taylor JMG, Maciejewski B Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988, 14:751.
246. Travis EL, Terry NHA Cell depletion and initial and chronic responses in normal tissues. Radiation tolerance of normal tissues: frontiers of radiation therapy and oncology 1989, vol 23:41-59. Karger, Basel.
247. Thames HD, Hendry JH Fractionation in radiotherapy 1987, Taylor and Francis, Philadelphia.
248. Tubiana M Can we reduce the incidence of second malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009, 91:4-15.
249. Ng AK, Travis LB Subsequent malignant neoplasms in cancer survivors. Cancer J 2008, 14:429-434.
250. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's Disease. J Natl Cancer Inst 2002, 94:182-192.
251. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's Disease. JAMA 2003, 290:465-475.
252. Kleinerman RA, Boice JD, Storm HH, et al. Second primary cancer after treatment for cervical cancer. Cancer 1995, 76:442-452.
253. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma. An extended follow-up. J Clin Oncol 2005, 23:2272-2279.
254. Hall EJ Is there a place for quantitative risk assessment?. J Radiol Prot 2009, 29:A171-A184.
255. Fowler JF, Stern BE Dose-time relationships in radiotherapy and the validity of cell survival curve models. Br J Radiol 1963, 36:163-173.
256. Withers HR The four R's of radiotherapy. Advances in radiation biology 1975, vol 5:241-271. Academic Press, New York.
257. Bedford JS, Hall EJ Survival of HeLa cells cultured in vitro and exposed to protracted gamma irradiation. Br J Radiol 1964, 39:896-900.
258. Hall EJ, Bedford JS Dose-rate. Its effect on the survival of HeLa cells irradiated with gamma-rays. Radiat Res 1964, 22:305-315.
259. Szechter A, Schwarz G Dose-rate effects, fractionation and cell survival at lower temperatures. Radiat Res 1977, 71:593-613.
260. Mitchell JB, Bedford JS, Bailey SM Dose-rate effects in plateau-phase cultures of S3 HeLa and V79 cells. Radiat Res 1979, 79:552-567.
261. Wells RL, Bedford JS Dose-rate effects in mammalian cells. IV. Repairable and nonrepairable damage in noncycling C3H 10T1/2 cells. Radiat Res 1983, 94:105-134.
262. Zeman EM, Bedford JS Dose-rate effects in mammalian cells. V. Dose fractionation effects in noncycling C3H 10T1/2 cells. Int J Radiat Oncol Biol Phys 1984, 10:2089-2098.
263. Dutreix J, Wambersie A, Bounik C Cellular recovery in human skin reactions: application to dose fraction number overall time relationship in radiotherapy. Eur J Cancer 1973, 9:159-167.
264. Ellis F Relationship of biological effect to dose-time-fractionation factors in radiotherapy. Current topics in radiation research 1968, 357-397. North Holland, Amsterdam. M. Ebert, M. Howard (Eds.).
265. Ellis F Dose, time and fractionation. A clinical hypothesis. Clin Radiol 1969, 20:1-8.
266. Orton CG, Ellis F A simplification in the use of the NSD concept in practical radiotherapy. Br J Radiol 1973, 46:529-537.
267. Kirk J, Gray WM, Watson R Cumulative radiation effect. Part I, Fractionated treatment regimes. Clin Radiol 1971, 22:145-155.
268. Denekamp J Changes in the rate of proliferation in normal tissues after irradiation. Radiation research: biomedical, chemical and physical perspectives 1975, 810-825. Academic Press, New York. O. Nygaard, H.I. Adler, W.K. Sinclair (Eds.).
269. Douglas BG, Fowler JF The effect of multiple small doses of X-rays on skin reactions in the mouse and a basic interpretation. Radiat Res 1976, 66:401-426.
270. Thames HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation. Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982, 8:219-226.
271. Withers HR, Thames HD, Peters LJ Differences in the fractionation response of acutely and late-responding tissues. Progress in radio oncology ii 1982, 287-296. Raven Press, New York. K.H. Karcher, H.D. Kogelnik, G. Reinartz (Eds.).
272. Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: a review of human data. Radiother Oncol 1990, 19:219-235.
273. Thames HD, Peters LJ, Withers HR, et al. Accelerated fractionation vs. hyperfractionation: rationale for several treatments per day. Int J Radiat Oncol Biol Phys 1983, 9:127-138.
274. Miles EF, Lee WR Hypofractionation for prostate cancer. A critical review. Semin Radiat Oncol 2008, 18:41-47.
275. Brenner DJ The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18:234-239.
276. Kirkpatrick JP, Meyer JJ, Marks LB The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008, 18:240-243.
277. Fowler JF, Harari PM, Leborgne F, et al. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003, 69:161-168.
278. Lee AWM, Sze W-M, Fowler JF, et al. Caution on the use of altered fractionation for nasopharyngeal carcinoma. Radiother Oncol 1999, 52:201-211.
279. Fowler JF Repair between dose fractions. A simpler method of analyzing and reporting apparently bioexponential repair. Radiat Res 2002, 158:141-151.
280. Fowler JF, Welsh JS, Howard SP Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 2004, 59:242-249.
281. Gasinska A, Fowler JF, Lind BK, et al. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation alone. Acta Oncol 2004, 43:657-666.
282. Ellsworth DL, Ellsworth RE, Liebman MN, et al. Genomic instability in histologically normal breast tissues. Implications for carcinogenesis. Lancet Oncol 2004, 5:753-758.
283. Streffer C Bystander effects, adaptive response and genomic instability induced by prenatal irradiation. Mutat Res 2004, 568:79-87.
284. Croce CM Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
285. Ballestar E, Esteller M Chapter 9. Epigentic gene regulation in cancer. Adv Genet 2008, 61:247-267.
286. Prise KM, O'Sullivan JM Radiation-induced bystander signalling in cancer therapy. Nature Rev Cancer 2009, 9:351-360.
287. Rodemann HP, Blaese MA Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007, 17:81-88.
288. Coleman CN, Stone HB, Moulder JE, et al. Medicine: Modulation of radiation injury. Science 2004, 304:693-694.
289. van der Meeren A, Mouthon MA, Vandamme M, et al. Combinations of cytokines promote survival of mice and limit acute radiation damage in concert with amelioration of vascular damage. Radiat Res 2004, 161:549-559.
290. Neumann AA, Reddel RR Telomere maintenance and cancer-look, no telomerase. Nature Rev Cancer 2002, 2:879-884.
291. Prise KM, Folkard M, Michael BD Bystander responses induced by low LET radiation. Oncogene 2003, 22:7043-7049.
292. Suit H, Skates S, Taghian A, et al. Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother Oncol 1992, 25:251-260.
293. Bergonié J, Tribondeau L Interpretation de quelques resultats de la radiotherapie. CR Acad Sci 1906, 143:983-988.
294. Regaud C, Ferroux R Discordance des effets de rayons X, d'une part dans le testicule, par le peau, d'autre part dans la fractionnement de la dose. CR Soc Biol 1927, 97:431-434.
295. Coutard H Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. AJR Am J Roentgenol 1932, 28:313-331.
296. Puck TT, Marcus PI Action of X-rays on mammalian cells. J Exp Med 1956, 103:653-666.
297. Hall EJ, Giaccia AJ Radiobiology for the radiologist 2006, Lippincott Williams & Wilkins, Philadelphia. ed 6.
298. Cleaver JE Xeroderma pigmentosum: a human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci USA 1969, 63:428-435.
299. Kastan MB, Bartek J Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
300. Painter RB, Young BR Radiosensitivity in ataxia-telangiectasia: a new explanation. Proc Natl Acad Sci USA 1980, 77:7315-7317.
301. Kellerer AM, Rossi HH The theory of dual radiation action. Cur Top Radiat Res Q 1972, 8:85-158.
302. Hewitt HB, Wilson CW A survival curve for cells irradiated in vivo. Nature 1959, 183:1060-1061.
303. Till JE, McCulloch EA A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-221.
304. Fowler JF, Morgan RL, Silvester JA, et al. Experiments with fractionated X-ray treatment of the skin of pigs. I. Fractionation up to 28 days. Br J Radiol 1963, 36:188-196.
305. Elkind MM, Sutton H X-ray damage and recovery in mammalian cells. Nature 1959, 184:1293-11295.
306. Phillips RA, Tolmach LJ Repair of potentially lethal damage in X-irradiated HeLa cells. Radiat Res 1966, 29:413-432.
307. Terasima T, Tolmach LJ Changes in X-ray sensitivity of HeLa cells during the division cycle. Nature 1961, 190:1210-1211.
308. Barendsen GW Responses of cultured cells, tumors and normal tissues to radiations of different linear energy transfer. Curr Top Radiat Res Q 1968, 4:293-356.
309. Thomlinson RH, Gray LH The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
310. Powers WE, Tolmach LJ A multicomponent X-ray survival curve for mouse lymphosarcoma cells irradiated. Nature 1963, 197:710-711.
311. Moulder JE, Rockwell S Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 1984, 10:695-712.
312. Kallman RF The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972, 105:135-142.
313. Brown JM Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979, 52:650-656.
314. Basic clinical radiobiology 2009, Hodder Arnold, London. ed 4. M. Joiner, A. van der Kogel (Eds.).
315. Overgaard J, Hansen HS, Anderson AP, et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989, 16:1065-1068.
316. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14:831-838.
317. Chapman JD, Franko AJ, Sharplin J A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981, 43:546-550.
318. Yuhas JM, Spellman JM, Culo F The role of WR 2721 in radiotherapy and/or chemotherapy. Radiation sensitizers 1980, 303-308. Masson, New York. L. Brady (Ed.).
319. Brown JM SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 1993, 67:1163-1170.
320. Mitchell JB, Russo A, Cook JA, et al. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol 1989, 56:827-836.
321. Marcu L, Olver I Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 2006, 1:71-879.
322. Rubin P, Casarett GW Clinical radiation pathology 1968, WB Saunders, Philadelphia.
323. Michalowski A Effects of radiation on normal tissues: hypothetical mechanisms and limitations of in situ assays of clonogenicity. Radiat Environ Biophys 1981, 19:157-172.
324. Mendelsohn ML The growth fraction: a new concept applied to tumors. Science 1960, 132:1496-1497.
325. Steel GG Growth kinetics of tumours 1977, Clarendon Press, Oxford.
326. Tannock IF, Hill RP, Bristow RG, et al. The basic science of oncology 2005, McGraw-Hill Companies, New York. ed 4.
327. Begg AC, Hofland I, Van Glabekke M Predictive value of potential doubling time for radiotherapy of head and neck tumour patients: results from the EORTC Cooperative Trial 22857. Semin Radiat Oncol 1992, 2:22-25.
328. Withers HR, Taylor JMG, Maciejewski B The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
329. Fowler JF The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.
330. Mettler FA, Upton AC Medical effects of ionizing radiation 2008, WB Saunders Company, Philadelphia. ed 3.
331. Brenner DJ, Hall EJ Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007, 357:2277-2284.
332. Fajardo LF Pathology of radiation injury 1982, Masson Publishing, New York.
333. Withers HR, Taylor JMG, Maciejewski B Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988, 14:751.
334. Thames HD, Hendry JH Fractionation in radiotherapy 1987, Taylor and Francis, Philadelphia.
335. Ng AK, Travis LB Subsequent malignant neoplasms in cancer survivors. Cancer J 2008, 14:429-434.
336. Withers HR The four R's of radiotherapy. Advances in radiation biology 1975, vol 5:241-271. Academic Press, New York.
337. Ellis F Dose, time and fractionation: a clinical hypothesis. Clin Radiol 1969, 20:1-8.
338. Denekamp J Changes in the rate of proliferation in normal tissues after irradiation. Radiation research: biomedical, chemical and physical perspectives 1975, 810-825. Academic Press, New York. O. Nygaard, H.I. Adler, W.K. Sinclair (Eds.).
339. Thames HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982, 8:219-226.
340. Streffer C Bystander effects, adaptive response and genomic instability induced by prenatal irradiation. Mutat Res 2004, 568:79-87.
341. Coleman CN, Stone HB, Moulder JE, et al. Medicine. Modulation of radiation injury. Science 2004, 304:693-694.